SCHEMBL3070904

SCHEMBL3070904

Cc1cc(OCCCCl)ccc1-c1nc(CCl)co1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.37
ACACA Q13085 1/20 0.37
HRH3 Q9Y5N1 6/20 0.36
FFAR4 Q5NUL3 1/20 0.35
ESR1 P03372 4/20 0.35
ESR2 Q92731 4/20 0.35
NPC1 O15118 2/20 0.34
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C19 P33261 1/20 0.33
PDIA6 Q15084 1/20 0.33
PTPN11 Q06124 1/20 0.33
MEN1 O00255 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3077580 0.85 PPARA (0.37) HRH3FFAR4ESR1ESR2PTPN11
SCHEMBL3076349 0.83 HRH3 (0.58) HRH3ESR1ESR2KDM4E
SCHEMBL5185655 0.78 HRH4 (0.44) HRH3KCNH2
SCHEMBL3079617 0.78 HRH3 (0.53) HRH3NPC1KDM4ECYP3A4CYP2D6
SCHEMBL3073429 0.76 FFAR1 (0.41) HRH3KDM4ECYP1A2MAPTCYP2C19
SCHEMBL3081268 0.74 HRH3 (0.52) HRH3NPC1KDM4ECYP3A4CYP2D6
SCHEMBL6487009 0.73 NPC1 (0.46) NPC1KDM4ECYP1A2MAPTCYP2C19
SCHEMBL3084880 0.72 HRH3 (0.50) HRH3NPC1KDM4EMAPTPTPN11
SCHEMBL5660767 0.69 DRD2 (0.56) NPC1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL3060204 0.67 PTPN11 (0.40) HRH3FFAR4PTPN11KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP claimed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP disclosed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR ACACB 1749/4885ACACA 1080/4885HRH3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.